Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8449)
All Articles published online
|
Publishing Process of This Article
|
Feb 14, 2015 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Rencz F, Péntek M, Bortlik M, Zagorowicz E, Hlavaty T, Śliwczyński A, Diculescu MM, Kupcinskas L, Gecse KB, Gulácsi L, Lakatos PL. Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. World J Gastroenterol 2015; 21(6): 1728-1737 [PMID: 25684937 DOI: 10.3748/wjg.v21.i6.1728] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i6/1728.htm |
| Number | Citing Articles |
| 1 |
Petra Baji, László Gulácsi, Valentin Brodszky, Zsuzsanna Végh, Silvio Danese, Peter M Irving, Laurent Peyrin‐Biroulet, Stefan Schreiber, Fanni Rencz, Péter L Lakatos, Márta Péntek. Cost‐effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe. United European Gastroenterology Journal 2018; 6(2): 310 doi: 10.1177/2050640617708952
|
| 2 |
Brian Godman, Magdalene Wladysiuk, Stuart McTaggart, Amanj Kurdi, Eleonora Allocati, Mihajlo Jakovljevic, Francis Kalemeera, Iris Hoxha, Anna Nachtnebel, Robert Sauermann, Manfred Hinteregger, Vanda Marković-Peković, Biljana Tubic, Guenka Petrova, Konstantin Tachkov, Juraj Slabý, Radka Nejezchlebova, Iva Selke Krulichová, Ott Laius, Gisbert Selke, Irene Langner, András Harsanyi, András Inotai, Arianit Jakupi, Svens Henkuzens, Kristina Garuolienė, Jolanta Gulbinovič, Patricia Vella Bonanno, Jakub Rutkowski, Skule Ingeberg, Øyvind Melien, Ileana Mardare, Jurij Fürst, Sean MacBride-Stewart, Carol Holmes, Caridad Pontes, Corinne Zara, Marta Turu Pedrola, Mikael Hoffmann, Vasileios Kourafalos, Alice Pisana, Rita Banzi, Stephen Campbell, Bjorn Wettermark, Kumud Kafle. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. BioMed Research International 2021; 2021: 1 doi: 10.1155/2021/9996193
|
| 3 |
László Gulácsi, Fanni Rencz, Gyula Poór, Zoltán Szekanecz, Valentin Brodszky, Petra Baji, Márta Péntek. Patients’ access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. Annals of the Rheumatic Diseases 2016; 75(5): 942 doi: 10.1136/annrheumdis-2015-208741
|
| 4 |
Daniel C. Baumgart, Laurent Misery, Sue Naeyaert, Peter C. Taylor. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00279
|
| 5 |
Petra Baji, László Gulácsi, Petra A. Golovics, Barbara D. Lovász, Márta Péntek, Valentin Brodszky, Fanni Rencz, Péter L. Lakatos. Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists. Value in Health Regional Issues 2016; 10: 85 doi: 10.1016/j.vhri.2016.07.004
|
| 6 |
Michael K Zheng, David Q Shih, Gary C Chen. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World Journal of Gastroenterology 2017; 23(11): 1932-1943 doi: 10.3748/wjg.v23.i11.1932
|
| 7 |
Walter Reinisch, Krisztina Gecse, Jonas Halfvarson, Peter M Irving, Jørgen Jahnsen, Laurent Peyrin-Biroulet, Gerhard Rogler, Stefan Schreiber, Silvio Danese. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease. Inflammatory Bowel Diseases 2021; 27(1): 106 doi: 10.1093/ibd/izaa078
|
| 8 |
Oliver von Richter, Lena Lemke, Halimuniyazi Haliduola, Rainard Fuhr, Thomas Koernicke, Ellen Schuck, Maria Velinova, Andrej Skerjanec, Johann Poetzl, Julia Jauch-Lembach. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods. Expert Opinion on Biological Therapy 2019; 19(10): 1075 doi: 10.1080/14712598.2019.1571580
|
| 9 |
Ana I. Sánchez-Garrido, Vanessa Prieto-Vicente, Víctor Blanco-Gozalo, Miguel Arévalo, Yaremi Quiros, Daniel López-Montañés, Francisco J. López-Hernández, Antonio Rodríguez-Pérez, José M. López-Novoa. Preventive Effect of Cardiotrophin-1 Administration before DSS-Induced Ulcerative Colitis in Mice. Journal of Clinical Medicine 2019; 8(12): 2086 doi: 10.3390/jcm8122086
|
| 10 |
Cristina Bezzio, Nicola Imperatore, Alessandro Armuzzi, Fernando Rizzello, Gianpiero Manes, Fabrizio Bossa, Emma Calabrese, Flavio Caprioli, Marco Daperno, Filippo Mocciaro, Ambrogio Orlando, Claudio Papi, Antonio Rispo, Simone Saibeni. Barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease. GastroHep 2019; 1(3): 93 doi: 10.1002/ygh2.331
|
| 11 |
|
| 12 |
Márta Péntek, Peter L Lakatos, Talitha Oorsprong, László Gulácsi, Milena Pavlova, Wim Groot, Fanni Rencz, Valentin Brodszky, Petra Baji, Crohn’s Disease Research Group. Access to biologicals in Crohn’s disease in ten European countries. World Journal of Gastroenterology 2017; 23(34): 6294-6305 doi: 10.3748/wjg.v23.i34.6294
|
| 13 |
Peter L. Lakatos, Nora Sipeki, Gyorgy Kovacs, Eszter Palyu, Gary L. Norman, Zakera Shums, Petra A. Golovics, Barbara D. Lovasz, Peter Antal-Szalmas, Maria Papp. Risk Matrix for Prediction of Disease Progression in a Referral Cohort of Patients with Crohn’s Disease. Journal of Crohn's and Colitis 2015; 9(10): 891 doi: 10.1093/ecco-jcc/jjv127
|
| 14 |
Aleksandra Sobolewska-Włodarczyk, Ewa Walecka-Kapica, Marcin Włodarczyk, Anita Gąsiorowska. Nutritional Status Indicators as a Predictor of Achieving Remission at Week 14 during Vedolizumab Therapy in Patients with Ulcerative Colitis: A Pilot Study. Nutrients 2023; 15(1): 240 doi: 10.3390/nu15010240
|
| 15 |
Mariángeles González-Fernández, Elena Villamañán, Inmaculada Jiménez-Nácher, Francisco Moreno, Chamaida Plasencia, Francisco Gaya, Alicia Herrero, Alejandro Balsa. Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price. International Journal of Clinical Pharmacy 2018; 40(6): 1528 doi: 10.1007/s11096-018-0703-z
|
| 16 |
Ruifeng Song, Ya Li, Weiwei Hao, Bingxue Wang, Lei Yang, Feng Xu. Identification and analysis of key genes associated with ulcerative colitis based on DNA microarray data. Medicine 2018; 97(21): e10658 doi: 10.1097/MD.0000000000010658
|
| 17 |
Jiyoun Kim, Dongmun Ha, Inmyung Song, Haesun Park, Sang‐Won Lee, Eui‐Kyung Lee, Ju‐Young Shin. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real‐world evidence using a nationwide database. International Journal of Rheumatic Diseases 2018; 21(6): 1227 doi: 10.1111/1756-185X.13295
|
| 18 |
Mariángeles González Fernández, Elena Villamañán, Inmaculada Jiménez-Nácher, Francisco Moreno, Chamaida Plasencia, Francisco Gayá, Alicia Herrero, Alejandro Balsa. Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price. Reumatología Clínica 2021; 17(6): 335 doi: 10.1016/j.reuma.2019.10.004
|
| 19 |
Christian Schoergenhofer, Michael Schwameis, Christa Firbas, Johann Bartko, Ulla Derhaschnig, Robert M Mader, Raute Sunder Plaßmann, Petra Jilma-Stohlawetz, Kalpna Desai, Priya Misra, Ulrich Jäger, Bernd Jilma. Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-017-17934-6
|
| 20 |
Yongwei Lin, Zhipeng Zhou, Lang Xie, Yongsheng Huang, Zhenghua Qiu, Lili Ye, Chunhui Cui. Effects of miR-939 and miR-376A on ulcerative colitis using a decoy strategy to inhibit NF-κB and NFAT expression. European Journal of Histochemistry 2022; 66(1) doi: 10.4081/ejh.2022.3316
|
| 21 |
Fanni Rencz, László Gulácsi, Márta Péntek, Krisztina B. Gecse, Axel Dignass, Jonas Halfvarson, Fernando Gomollón, Petra Baji, Laurent Peyrin-Biroulet, Peter L. Lakatos, Valentin Brodszky. Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe. Expert Review of Pharmacoeconomics & Outcomes Research 2017; 17(6): 597 doi: 10.1080/14737167.2017.1322509
|
| 22 |
Cécile Rémuzat, Julie Dorey, Olivier Cristeau, Dan Ionescu, Guerric Radière, Mondher Toumi. Key drivers for market penetration of biosimilars in Europe. Journal of Market Access & Health Policy 2017; 5(1): 1272308 doi: 10.1080/20016689.2016.1272308
|
| 23 |
Tim A. Kanters, Jelena Stevanovic, Isabelle Huys, Arnold G. Vulto, Steven Simoens. Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel. Frontiers in Pharmacology 2017; 8 doi: 10.3389/fphar.2017.00322
|
| 24 |
Tocia Cristina, Achim Anda Carmen, Alexandrescu Luana, Dumitru Eugen. Inflammatory Bowel Diseases: Focus on Therapy. ARS Medica Tomitana 2018; 24(1): 9 doi: 10.2478/arsm-2018-0003
|
| 25 |
Petra Baji, László Gulácsi, Barbara D. Lovász, Petra A. Golovics, Valentin Brodszky, Márta Péntek, Fanni Rencz, Péter L. Lakatos. Treatment preferences of originator versus biosimilar drugs in Crohn’s disease; discrete choice experiment among gastroenterologists. Scandinavian Journal of Gastroenterology 2016; 51(1): 22 doi: 10.3109/00365521.2015.1054422
|
| 26 |
Karim Sariahmed, Joshua Kurian, Anjani K. Singh, Christopher Leyton, Aurelia Minuti, Elina Jerschow, Shitij Arora, Sunit P. Jariwala. Social, political, and economic determinants of access to biologics: A scoping review of structural determinants in the clinical disparities literature. Research in Social and Administrative Pharmacy 2022; 18(12): 4038 doi: 10.1016/j.sapharm.2022.07.047
|
| 27 |
Zornitsa Mitkova, Ivan Manev, Konstantin Tachkov, Vladimira Boyadzhieva, Nikolay Stoilov, Miglena Doneva, Guenka Petrova. How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example. Healthcare 2023; 11(17): 2427 doi: 10.3390/healthcare11172427
|
| 28 |
Andras Inotai, Marcell Csanadi, Guenka Petrova, Maria Dimitrova, Tomasz Bochenek, Tomas Tesar, Kristina York, Leos Fuksa, Alexander Kostyuk, Laszlo Lorenzovici, Vitaly Omelyanovskiy, Katalin Egyed, Zoltan Kalo. Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. BioMed Research International 2018; 2018: 1 doi: 10.1155/2018/9597362
|
| 29 |
Zsombor Zrubka, Zsuzsanna Beretzky, Zoltán Hermann, Valentin Brodszky, László Gulácsi, Fanni Rencz, Petra Baji, Dominik Golicki, Valentina Prevolnik-Rupel, Márta Péntek. A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. The European Journal of Health Economics 2019; 20(S1): 119 doi: 10.1007/s10198-019-01069-8
|
| 30 |
Aditi Kumar, Nuha Yassin, Alexandra Marley, Vittoria Bellato, Caterina Foppa, Gianluca Pellino, Pär Myrelid, Monica Millan, Beatriz Gros, Nicolas Avellaneda, Ignacio Catalan-Serra, Alaa El-Hussuna, João A. Cunha Neves, Joana Roseira, Miguel F. Cunha, Bram Verstockt, Dominik Bettenworth, Diane Mege, Matthew J. Brookes. Crossing barriers: the burden of inflammatory bowel disease across Western Europe. Therapeutic Advances in Gastroenterology 2023; 16 doi: 10.1177/17562848231218615
|
| 31 |
Anne Lund Krarup, Lone Larsen, Alev Büyükuslu Nayeb, Simon Grøntved, Søren Paaske Johnsen, Mette Esbjørn, Jan Fallingborg, Gunnar Lauge Nielsen, Kristine Allin, Tine Jess, Anne Estrup Olesen. Less prevalent use of biologics for inflammatory bowel disease in patients from Non-Academic hospitals – a Danish register-based study of a region with 580,000 citizens. Scandinavian Journal of Gastroenterology 2023; 58(5): 477 doi: 10.1080/00365521.2022.2143726
|
| 32 |
Saumya Pandey, Afroz Alam. Advanced Pharmacological Uses of Medicinal Plants and Natural Products. Advances in Medical Diagnosis, Treatment, and Care 2020; : 269 doi: 10.4018/978-1-7998-2094-9.ch014
|
| 33 |
Cécile Rémuzat, Anna Kapuśniak, Aleksandra Caban, Dan Ionescu, Guerric Radière, Cyril Mendoza, Mondher Toumi. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. Journal of Market Access & Health Policy 2017; 5(1): 1307315 doi: 10.1080/20016689.2017.1307315
|
| 34 |
Y. Xun, F. Yan, H. Zhu, L. Feng, D. Zhang, Y. Xue, F. He, S. Wang. Oral administration of Lactobacillus paracasei N1115 on neonatal mice prevents the intestinal inflammation in adulthood. Letters in Applied Microbiology 2022; 75(2): 330 doi: 10.1111/lam.13729
|
| 35 |
Fanni Rencz, Peter L. Lakatos, László Gulácsi, Valentin Brodszky, Zsuzsanna Kürti, Szilvia Lovas, János Banai, László Herszényi, Tamás Cserni, Tamás Molnár, Márta Péntek, Károly Palatka. Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s disease. Quality of Life Research 2019; 28(1): 141 doi: 10.1007/s11136-018-2003-4
|
| 36 |
Nan Li, Xue-Ming Wang, Li-Jun Jiang, Meng Zhang, Na Li, Zhen-Zhen Wei, Nan Zheng, Ya-Jiao Zhao. Effects of endoplasmic reticulum stress on the expression of inflammatory cytokines in patients with ulcerative colitis. World Journal of Gastroenterology 2016; 22(7): 2357-2365 doi: 10.3748/wjg.v22.i7.2357
|
| 37 |
Péter Kunovszki, Kata Judit Szántó, Judit Gimesi-Országh, Péter Takács, András Borsi, Anita Bálint, Klaudia Farkas, Ágnes Milassin, Péter L. Lakatos, Tamás Szamosi, Tamás Molnár. Epidemiological data and utilization patterns of anti-TNF alpha therapy in the Hungarian ulcerative colitis population between 2012-2016. Expert Opinion on Biological Therapy 2020; 20(4): 443 doi: 10.1080/14712598.2020.1718097
|
| 38 |
Mariángeles González Fernández, Elena Villamañán, Inmaculada Jiménez-Nácher, Francisco Moreno, Chamaida Plasencia, Francisco Gayá, Alicia Herrero, Alejandro Balsa. Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price. Reumatología Clínica (English Edition) 2021; 17(6): 335 doi: 10.1016/j.reumae.2019.10.007
|
| 39 |
Michal Prokopič, Georgiana Gilca-Blanariux, Peter Lietava, Anca Trifan, Anna Pietrzak, Agata Ladic, Marko Brinar, Svetlana Turcan, Tamás Molnár, Peter Bánovčin, Milan Lukáš. Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis. Therapeutic Advances in Gastroenterology 2023; 16 doi: 10.1177/17562848231174290
|
| 40 |
Zsuzsanna Kurti, Akos Ilias, Lorant Gonczi, Zsuzsanna Vegh, Petra Fadgyas-Freyler, Gyula Korponay, Petra A. Golovics, Barbara D. Lovasz, Peter L. Lakatos. Therapeutic preferences and outcomes in newly diagnosed patients with Crohn’s diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database. BMC Gastroenterology 2018; 18(1) doi: 10.1186/s12876-018-0746-6
|
| 41 |
Zsuzsanna Kurti, Zsuzsanna Vegh, Petra A. Golovics, Petra Fadgyas-Freyler, Krisztina B. Gecse, Lorant Gonczi, Judit Gimesi-Orszagh, Barbara D. Lovasz, Peter L. Lakatos. Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database. Digestive and Liver Disease 2016; 48(11): 1302 doi: 10.1016/j.dld.2016.07.012
|
| 42 |
Archana Kumari, Deo Nandan Prasad, Sahil Kumar, Rajesh K. Singh. Clinical Benefits of Switching from Original Infliximab to its Biosimilar (CT-P13) as a Potential TNF-α Inhibitor. Journal of Exploratory Research in Pharmacology 2020; 0(000): 1 doi: 10.14218/JERP.2020.00004
|
| 43 |
Péter Kunovszki, Ágnes Milassin, Judit Gimesi-Országh, Péter Takács, Kata Szántó, Anita Bálint, Klaudia Farkas, András Borsi, Péter L. Lakatos, Tamás Szamosi, Tamás Molnár, Valérie Pittet. Epidemiology, mortality and prevalence of colorectal cancer in ulcerative colitis patients between 2010-2016 in Hungary – a population-based study. PLOS ONE 2020; 15(5): e0233238 doi: 10.1371/journal.pone.0233238
|
| 44 |
Morton Scheinberg, Carlos Pineda, Gilberto Castañeda-Hernández, Juan José Zarbá, Aderson Damião, Luiz H Arantes Jr, Ira Jacobs. Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America. mAbs 2018; 10(6): 827 doi: 10.1080/19420862.2018.1484977
|
| 45 |
Lissy de Ridder, Amit Assa, Jiri Bronsky, Claudio Romano, Richard K. Russell, Nadeem A. Afzal, Almuthe C. Hauer, Daniela Knafelz, Paolo Lionetti, Caterina Strisciuglio, Gábor Veres, Harland Winter, Victorien M. Wolters, Malgorzata Sladek, Arnold G. Vulto, Jorge A. Dias. Use of Biosimilars in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition 2019; 68(1): 144 doi: 10.1097/MPG.0000000000002141
|
| 46 |
Jürgen Braun, Alex Kudrin. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health. Biologicals 2016; 44(4): 257 doi: 10.1016/j.biologicals.2016.03.006
|
| 47 |
Christopher J. Edwards, Jana Hercogová, Helene Albrand, Aurelian Amiot. Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. Expert Opinion on Biological Therapy 2019; 19(10): 1001 doi: 10.1080/14712598.2019.1610381
|
| 48 |
László Gulácsi, Valentin Brodszky, Petra Baji, HoUng Kim, Su Yeon Kim, Yu Young Cho, Márta Péntek. Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Review of Clinical Immunology 2015; 11(sup1): 43 doi: 10.1586/1744666X.2015.1090313
|
| 49 |
Halina Cichoż-Lach, Agata Michalak, Maria Kopertowska-Majchrzak, Piotr Eder, Kamila Stawczyk-Eder, Katarzyna Waszak, Renata Talar-Wojnarowska, Hubert Zatorski, Anna Solarska-Półchłopek, Jarosław Chmielnicki, Rafał Filip, Anna Pękala, Maria Janiak, Krzysztof Skrobot, Ewa Kasińska, Michał Krogulecki, Piotr Królikowski, Maria Kłopocka, Ariel Liebert, Elżbieta Poniewierka, Izabela Smoła, Anita Gąsiorowska, Aleksandra Kaczka, Joanna Wypych, Krzysztof Wojciechowski, Szymon Drygała, Edyta Zagórowicz. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therapeutic Advances in Gastroenterology 2021; 14: 175628482110364 doi: 10.1177/17562848211036456
|
| 50 |
Zsuzsanna Kurti, Lorant Gonczi, Peter L. Lakatos. Progress with infliximab biosimilars for inflammatory bowel disease. Expert Opinion on Biological Therapy 2018; 18(6): 633 doi: 10.1080/14712598.2018.1469620
|
| 51 |
Till Uhlig, Guro L. Goll. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology 2017; 56(suppl_4): iv49 doi: 10.1093/rheumatology/kex276
|
| 52 |
Laszlo Gulacsi, Marta Pentek, Fanni Rencz, Valentin Brodszky, Petra Baji, Zsuzsanna Vegh, Krisztina B Gecse, Silvio Danese, Laurent Peyrin-Biroulet, Peter L. Lakatos. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Current Medicinal Chemistry 2019; 26(2): 259 doi: 10.2174/0929867324666170406112304
|
| 53 |
Jia-Mei Rong, Juan Luo, Qi Huang, Ying-Lei Miao. Individualized selection of biological agents in treatment of inflammatory bowel disease. World Chinese Journal of Digestology 2021; 29(15): 893 doi: 10.11569/wcjd.v29.i15.893
|
| 54 |
Valentin Brodszky, Fanni Rencz, Márta Péntek, Petra Baji, Péter L Lakatos, László Gulácsi. A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Review of Pharmacoeconomics & Outcomes Research 2015; : 1 doi: 10.1586/14737167.2015.1067142
|
| 55 |
Yazed AlRuthia, Othman Alharbi, Abdulrahman M. Aljebreen, Nahla A. Azzam, Majid A. Almadi, Ohud H. Bahari, Khalid A. Almalki, Abdulaziz T. Atham, Ahmed S. Alanazi, Maria Saeed, Baraa HajkhderMullaissa, Mohammad Alsenaidy, Bander Balkhi. Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia. Cost Effectiveness and Resource Allocation 2019; 17(1) doi: 10.1186/s12962-019-0194-3
|
| 56 |
Fanni Rencz, Peep F. M. Stalmeier, Márta Péntek, Valentin Brodszky, Gábor Ruzsa, Lóránt Gönczi, Károly Palatka, László Herszényi, Eszter Schäfer, János Banai, Mariann Rutka, László Gulácsi, Peter L. Lakatos. Patient and general population values for luminal and perianal fistulising Crohn’s disease health states. The European Journal of Health Economics 2019; 20(S1): 91 doi: 10.1007/s10198-019-01065-y
|
| 57 |
Dominik Saul, Robyn Laura Kosinsky. Dextran Sodium Sulfate-induced Colitis as a Model for Sarcopenia in Mice. Inflammatory Bowel Diseases 2020; 26(1): 56 doi: 10.1093/ibd/izz127
|
| 58 |
Yazed AlRuthia, Majid Almadi, Abdulrahman Aljebreen, Nahla Azzam, Wejdan Alsharif, Hala Alrasheed, Ghadah Almuaythir, Maria Saeed, Baraa HajkhderMullaissa, Othman Alharbi. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia. Journal of Medical Economics 2020; 23(10): 1102 doi: 10.1080/13696998.2020.1791889
|
| 59 |
Nemanja Damjanov, Sarolta Karpati, Lajos Kemeny, Noemi Bakos, Branislav Bobic, Maria Majdan, Witold Tlustochowicz, Petr Vitek, Eva Dokoupilova, Emre Aldinc, Annette Szumski. Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe. Journal of Dermatological Treatment 2018; 29(1): 8 doi: 10.1080/09546634.2017.1329509
|
| 60 |
F. Rencz, L. Kemény, J.Z. Gajdácsi, W. Owczarek, P. Arenberger, G.S. Tiplica, A. Stanimirović, M. Niewada, G. Petrova, L.T. Marinov, M. Péntek, V. Brodszky, L. Gulácsi. Use of biologics for psoriasis in Central and Eastern European countries. Journal of the European Academy of Dermatology and Venereology 2015; 29(11): 2222 doi: 10.1111/jdv.13222
|